Reuters logo
BRIEF-Anacor Pharma down in premarket after tavaborole trial results
January 29, 2013 / 1:12 PM / 5 years ago

BRIEF-Anacor Pharma down in premarket after tavaborole trial results

NEW YORK, Jan 29 (Reuters) - Anacor Pharmaceuticals Inc : * Anacor Pharma down 22.6 percent to $4 in premarket after tavaborole trial results

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below